Literature DB >> 8456079

Influence of dose range on degree of nonlinearity detected in dose-proportionality studies for drugs with saturable elimination: single-dose and steady-state studies.

T A Shepard1, N Lordi, P E Sparrow.   

Abstract

Deviation from proportionality occurs when the ratio of area under the curve (AUC) values is not equal to the ratio of administered doses. The degree of nonlinearity (fNL) can be quantitated as the ratio of AUCs divided by the ratio of doses. We explore positive deviation from proportionality (fNL > 1) using the classical Michaelis-Menten model of nonlinear elimination after a single dose (n = 1) or at steady state (ss). The degree of nonlinearity is related to the ratio of the highest dose to the lowest dose (Rd = DH/DL): fn = 1NL = (2 + Rd.epsilon)/(2 + epsilon), fssNL = (Rd.omega - 1)/(Rd.omega - Rd), where epsilon is the ratio of the initial concentration after the lowest dose to the Km (epsilon = DL/Km.V) and omega is the ratio of the Vmax to the average rate of input for the highest dose (omega = Vmax tau/F.DH). From these relationships, we find that (1) for single-dose studies, Km is the important Michaelis-Menten parameter, while Vmax is important at steady state; (2) the degree of nonlinearity cannot exceed the ratio of doses in single-dose studies, and when doses in extreme excess of Km.V are chosen, the degree of nonlinearity is equal to the dose range; and (3) at steady state, the degree of nonlinearity can exceed the ratio of doses and approaches infinity as the average input rate approaches Vmax. Literature data (phenytoin and ethanol) support these findings. We conclude that the degree of nonlinearity is not a useful measure of nonlinearity in and of itself and propose percentage saturation as being more informative.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456079     DOI: 10.1023/a:1018955315055

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  4 in total

1.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors:  N Gerber; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-05

2.  Serum-phenytoin levels in management of epilepsy.

Authors:  A Richens; A Dunlop
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

3.  Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin.

Authors:  N Gerber; D C Mays; K H Donn; A Laddu; R M Guthrie; P Turlapaty; C Y Quon; W K Rivenburg
Journal:  J Clin Pharmacol       Date:  1988-11       Impact factor: 3.126

4.  Ethanol 'dose-dependent' elimination: Michaelis-Menten v classical kinetic analysis.

Authors:  R E Rangno; J H Kreeft; D S Sitar
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

  4 in total
  2 in total

1.  Confidence interval criteria for assessment of dose proportionality.

Authors:  B P Smith; F R Vandenhende; K A DeSante; N A Farid; P A Welch; J T Callaghan; S T Forgue
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

2.  Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.

Authors:  Jianmin Duan; Michel Liuzzi; William Paris; Francine Liard; Abigail Browne; Nathalie Dansereau; Bruno Simoneau; Anne-Marie Faucher; Michael G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.